Photo of Jorg  Dietrich, MD, PhD

Jorg Dietrich, MD, PhD

  • Clinical Director, Cancer and Neurotoxicity Clinic and Brain Repair Research Program


Accepting New Patients




Centers & Specialties

Cancer Center

  • Neuro-Oncology (Brain)
Clinical Interests
  • Brain tumors
  • Myelin biology and white matter disease
  • Neurological complications of cancer therapy
  • Neural stem and progenitor cell biology
Medical Education
  • MMSc, Harvard University
  • MD, University of Giessen
  • PhD, University of Regensburg
  • Residency, Brigham and Women's Hospital|Residency, University of Regensburg
  • Fellowship, Massachusetts General Hospital
Board Certifications
  • Neurology
Foreign Languages
  • German
  • French
  • Boston: Massachusetts General Hospital
Existing Patients
Patient Gateway
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • BMC HealthNet Mass Health MCO/ACO
  • Cigna (PAL #'s)
  • Commonwealth Care Alliance
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • OSW - Vermont
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
  • Well Sense Pediatrics

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group
Provider Gender


Jorg Dietrich, MMSc MD PhD, is the Director of the Cancer & Neurotoxicity Clinic and Brain Repair Research Program at the MGH Cancer Center, and Assistant Professor of Neurology at Harvard Medical School. His clinical interests are the management of patients with brain tumors and neurologic complications of cancer therapy. His research activities include clinical, translational and basic research in the fields of brain tumor biology, neurotoxicity and brain repair mechanisms.He is author of over 100 publications, including original research articles, review papers, book chapters and other scientific contributions. His work has been supported by the NIH, the American Cancer Society, and the American Academy of Neurology.

Research & Publications

Research Summary

My main research focus has been the study of neural precursor cell biology in the context of neurological disease. Our work has shown that abnormal progenitor and stem cell function is underlying diverse neurological diseases, including leukodystrophies, viral infections, brain cancer and neurotoxicity following cancer therapy. Abnormal neural progenitor cell function has also tremendous implications for our understanding of conditions with chronic and progressive neurological impairment, such as neurodegenerative diseases.

An important area of our current investigation is the study of the cell-biological basis of neurotoxicity following cancer treatment. We were able to demonstrate that lineage-committed progenitor cells belong to the most sensitive cell populations to chemotherapy. These studies have provided the foundation for the development of neuroprotective and cellular repair strategies that are currently being assessed for their application in clinical trials.

Another focus of our current research studies is the characterization of the neurovascular niche. Neurogenesis and gliogenesis, the generation of new neurons and glia cells, occur in well-defined 'niches' composed of neural stem cells, progenitors, astrocytes, and vascular components. The neurovascular niche is therefore characterized by a intersection between neuroectodermal and mesenchymal cell system. The neurovascular niche is critically important in the formation of brain tumors, in treatment resistance and in tumor progression. Our studies aim to provide novel insights into the unique interplay between mesenchymal and neuroectodermal tissues and to identify novel therapeutic targets for tumor therapy and novel strategies to enhance endogenous brain repair.



  • Vaios EJ et al. Bone marrrow response as a potential biomarker of outcomes in glioblastoma. J Neurosurg. 2016; 14: 1-7.
  • Belkind-Gerson J et al. Engraftment of enteric neural progenitor cells into the injured adult brain. BMC Neuroscience 2016; 17: 5.
  • Miller JJ et al. Perspectives on investigational drugs and immunotherapies for glioblastoma. Exp Opin Investig Drugs 2016; 25(9): 1007-9.
  • Prust MJ et al. Standard Chemotherapy for glioblastoma results in progressive brain volume loss. Neurology 2015; 85(8): 683-91.
  • Dietrich J et al. Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience 2015; 309: 224-32.
  • Horky LL et al. Systemic chemotherapy decreases brain glucose metabolism. Ann Clin Transl Neurology. 2014; 1(10): 788-98.
  • Kaiser J et al.  Neural Correlates of chemotherapy-related cognitive impairment. Cortex. 2014; 54C:33-50.
  • Tanaka S et al. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nature Rev Clin Oncol. 2013; 10(1):14-26.
  • Dietrich J et al. Mechanisms of Disease: Neural Stem Cells and Gliomas. Nature Clinical Practice Oncology. 2008;5(7):393-404.
  • Dietrich J et al. Clinical Patterns and Biological Correlates of Cognitive Dysfunction Associated with Cancer Therapy. The Oncologist. 2008;13(12):1-13.
  • Dietrich J et al. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. Journal of Biology. 2006;5(22).
  • Dietrich J et al. EIF2B5 mutations compromise generation of GFAP+ astrocytes from neural precursors in Vanishing White Matter leukodystrophy. Nature Medicine. 2005;11(3):277-283.

News & Events

  • Study reveals effects of chemoradiation in brains of glioblastoma patients

    A study from MGH Cancer Center researchers – the first to examine the effects of combined radiation and chemotherapy on the healthy brain tissue of glioblastoma patients – reveals not only specific structural changes within patients’ brains but also that the effect of cancer therapy on the normal brain appears to be progressive and continues even after radiation therapy has ceased.


Neurology & Stroke Services
15 Parkman Street
Boston, MA 02114-3117
Phone: 617-724-8770
Fax: 617-724-8769

Back to Top